US President Donald Trump has announced steep tariffs on imported generic medicines. The move is designed to encourage pharmaceutical manufacturers to relocate production to the United States. Trump said generic medicines would remain tariff-free for two years from 1 August 2026. A 100% tariff would then apply for one year from August 2028. This would increase to 200% from August…
Tag: Donald Trump
-
US WHO Withdrawal Official, Organisation Plans Deep Cuts
The US WHO Withdrawal became effective in late January 2026, ending Washington’s formal membership in the World Health Organisation after a one-year notice period triggered by an executive order signed on Inauguration Day of Donald Trump’s second term. The administration argues the US pays more than peer nations and has criticised the WHO’s Covid-19 response and governance. The WHO disputes…
-
Global Malaria Crisis Deepens Amid US Cuts, Rising Resistance
The global malaria crisis is facing a severe and potentially irreversible setback, according to the World Health Organisation’s (WHO) latest report. Progress in fighting the disease has stagnated since 2015, and by 2024, key indicators show a dramatic regression that experts are calling catastrophic. Global Malaria Crisis Escalates With Alarming Statistics In 2024, malaria infected 282 million people and killed…
-
US Drug Prices Under Trump’s New Pharma Deals
Americans spend more on prescription drugs than any other nation. This fact is driven not just by volume but by staggering costs. Unlike in Europe, the US government has historically refrained from directly intervening in price setting. While modest changes under then-President Joe Biden offered some relief for seniors, his successor, Donald Trump, has vowed to aggressively slash US drug…
-
Obesity Drug Deal: Trump Cuts Prices for Patients
US President Donald Trump has announced a landmark deal with drugmakers Novo Nordisk and Eli Lilly, set to significantly reduce the price of hugely popular obesity drugs for millions of Americans. The agreement, unveiled at the White House, will slash costs for injectable treatments like Wegovy and Zepbound, as well as two forthcoming oral medications. The deal aims to save…
-
Pfizer Drug Pricing Deal Sees Stocks Soar
In a move heralded by President Donald Trump as a monumental victory for American consumers, pharmaceutical giant Pfizer has agreed to a deal that promises to slash the prices of some of its drugs. However, the market’s reaction has told a very different story. This reaction raises questions about the actual impact of the agreement on the firm’s bottom line…
-
HHS Restructuring Plan Blocked by Federal Court
A US Federal Appeals Court has maintained a block on the Trump administration’s ambitious and controversial plan to overhaul the Department of Health and Human Services (HHS). This move would have resulted in 10,000 job losses. Additionally, it would have caused a significant restructuring of key public health agencies. A three-judge panel of the Boston-based 1st US Circuit Court of…
-
Children’s Lives at Risk as US Proposes Slashing Funds for Gavi
In a move putting children’s lives at risk, the US government has announced its intention to cut funding for Gavi, the Vaccine Alliance. It is a key organisation credited with saving millions of lives through childhood immunisation. The decision comes at a critical time, as rising vaccine hesitancy contributes to a resurgence of preventable diseases like measles worldwide. The proposed…
-
Lower Pharmaceutical Prices: Trump’s Bold Ultimatum
President Donald Trump has dramatically escalated his campaign against high medicine costs. He issued a stark ultimatum to 17 of the world’s leading pharmaceutical firms. In a move aimed at achieving lower pharmaceutical prices, the President demanded that they slash prices for American consumers. He wants them to match what is paid in other developed nations, setting a 60-day deadline…
-
USAID Funding Cuts Could Trigger 14 Million Deaths by 2030
Deep and ongoing USAID funding cuts to the US Agency for International Development (USAID), coupled with its potential dismantling, could result in more than 14 million additional deaths across the globe by 2030. This is according to new research. The study, published in the prestigious medical journal The Lancet on Monday, 30 June, highlights the catastrophic human cost of the…
-
Trump’s Tariff Stick Won’t Bring Generic Drug Manufacturing Home
President Donald Trump’s administration has championed Trump’s Tariff Stick as a means to compel global industries to relocate manufacturing to the United States. However, for the generic drug sector, which supplies roughly 90% of all medicines consumed by Americans, Trump’s Tariff Stick is a blunt instrument with potentially damaging outcomes. Industry leaders are cautioning that, instead of encouraging domestic production,…